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Background
Epigenetic aberrations such as alterations in DNA methyl-
ation are a common hallmark of cancer. HPV genome
methylation profiling in normal, precursor, and invasive
lesion smears has shown that as lesion severity increases,
there is progressive hypomethylation on the LCR and E6
gene regions, suggesting that neoplastic transformation
can be suppressed by gene hypermethylation, whereas
hypomethylation accompanies or causes cervical cancer
progression. Because of that, some are argued on caution
against the use of epigenetic therapy for HPV-related
malignancies as it may act as a tumor promoter by
enhancing the expression of HPV oncoproteins. To
address this issue, herein we analyzed the effects of DNA
methylation and histone deacetylase inhibitors upon the
human papillomavirus early genes expression in cervical
cancer cell lines and patients.
Methods
CasKi, HeLa, CaLo, SiHa cell lines were studied. Cell pro-
liferation was assayed by MTT assay. E6/E7 expression by
RT-PCR, chromatin immunoprecipitation by ChiP and
methylation profile by PCR after McfBC digestion. Clini-
cal samples were taken from clinical studies performed
with hydralazine, valproate and both (BMC2005, Mol
Cancer 2005, in preparation). P53 expression and p53/E6
interaction were – analyzed by western blot and immuno-
precipitation assays.
Results
Our results demonstrate that hydralazine and valproate
induce growth inhibition in cervical cancer cells without
causing significant changes in the expression level of E6/
E7 transcript. Likewise, chromatin immunoprecipitation
assays demonstrate that hydralazine and valproate
induced no major changes in the acetylation status of H4
at the LCR of the HPV. The lack of significant changes at
the expression levels of viral E6/E7 viral oncogenes occurs
despite epigenetic drugs induced some degree of
hypomethylation at the viral LCR. E6/E7 expression
changes were minor and heterogenous in the postreat-
ment biopsies of patients treated with hydralazine, val-
proate or both. On the contrary, hydralazine and
valproate induce a strong increase in p53 at the protein
level which resulted from p53 protein acetylation which
protects its degradation by E6 leading to transactivation of
p53 targets such as the pro-apoptotic gene bax.
Conclusion
Hydralazine and valproate treatment not only fail to
increase HPV E6/E7 viral oncoprotein expresion but leads
to accumulation of p53 levels by its acetylation which
increases the transactivation function of p53. These data
suggest that hydralazine and valproate may increase the
efficacy of current cervical cancer treatments.
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